Eslicarbazepine acetate as monotherapy in clinical practice: Outcomes from Euro‐Esli

To assess the effectiveness and safety/tolerability of eslicarbazepine acetate (ESL) monotherapy in clinical practice in Europe.

[1]  Villanueva Vicente,et al.  THUR 058 Eslicarbazepine acetate as monotherapy in clinical practice , 2018, Journal of Neurology Neurosurgery & Psychiatry.

[2]  D. Costello,et al.  Real world experience with lacosamide monotherapy- a single center 1-year follow-up study , 2018, Epilepsy Research.

[3]  M. De Backer,et al.  Lacosamide monotherapy in clinical practice: A retrospective chart review , 2018, Acta neurologica Scandinavica.

[4]  C. Elger,et al.  Efficacy and safety of eslicarbazepine acetate versus controlled‐release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double‐blind, randomized, parallel‐group, multicenter study , 2018, Epilepsia.

[5]  N. Delanty,et al.  Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures , 2017, Journal of Neurology.

[6]  J. Ojeda,et al.  EARLY‐ESLI study: Long‐term experience with eslicarbazepine acetate after first monotherapy failure , 2017, Acta neurologica Scandinavica.

[7]  R. Toledano,et al.  Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study , 2017, Epilepsy & Behavior.

[8]  J. Chaves,et al.  Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study , 2017, Acta neurologica Scandinavica.

[9]  M. Holtkamp,et al.  Daten zum aktuellen Praxiseinsatz von Eslicarbazepinacetat in Deutschland , 2016, Zeitschrift für Epileptologie.

[10]  M. Holtkamp,et al.  Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy , 2016 .

[11]  T. Mayer,et al.  A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial‐onset seizures in daily clinical practice: The VITOBA study , 2015, Epilepsia.

[12]  R. Rocamora,et al.  Assessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests , 2015, Epilepsy Research.

[13]  L. Pazdera,et al.  Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study , 2015, BMC Neurology.

[14]  M. Sperling,et al.  Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: A randomized historical‐control phase III study based in North America , 2015, Epilepsia.

[15]  J. Chaves,et al.  Two-year follow-up with eslicarbazepine acetate: a consecutive, retrospective, observational study , 2014, Epilepsy Research.

[16]  J. Serratosa,et al.  Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study , 2014, Epilepsy Research.

[17]  J. Roquer,et al.  Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results. , 2014, Neurologia.

[18]  R. Rocamora,et al.  Post-authorisation study of eslicarbazepine as treatment for drug-resistant epilepsy: preliminary results☆☆☆ , 2014 .

[19]  M. Brodie,et al.  Safety and efficacy of eslicarbazepine acetate (zebinix) in everyday clinical practice using a retrospective multicentre audit , 2013, Journal of Neurological Sciences.

[20]  M. Brodie,et al.  Combining antiepileptic drugs—Rational polytherapy? , 2011, Seizure.

[21]  J. Cramer,et al.  The evolution of antiepileptic drug development and regulation , 2010, Epileptic disorders : international epilepsy journal with videotape.

[22]  T. Egberts,et al.  Clinical relevance of patients with epilepsy included in clinical trials , 2008, Epilepsia.

[23]  G. Pauletto,et al.  Oxcarbazepine reduces seizure frequency in a high proportion of patients with both newly diagnosed and refractory partial seizures in clinical practice , 2006, Seizure.

[24]  B. Passarella,et al.  Long-term treatment with oxcarbazepine in clinical practice. , 2005, Functional neurology.

[25]  M. Baulac.  Rational conversion from antiepileptic polytherapy to monotherapy. , 2003, Epileptic disorders : international epilepsy journal with videotape.

[26]  H. Meinardi,et al.  Reappraisal of Polytherapy in Epilepsy: A Critical Review of Drug Load and Adverse Effects , 1997, Epilepsia.